EyePoint Pharmaceuticals Inc
EYPT
View Detailed Chart
12.500USD
-0.560-4.29%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
1.04BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.29%
5 Days
-5.52%
1 Month
-28.82%
6 Months
-10.07%
Year to Date
-31.58%
1 Year
+111.51%
View Detailed Chart
TradingKey Stock Score of EyePoint Pharmaceuticals Inc
Currency: USD Updated: 2026-03-27Key Insights
EyePoint Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 66 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.42.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
EyePoint Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
EyePoint Pharmaceuticals Inc Highlights
StrengthsRisks
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Growing
The company is in a growing phase, with the latest annual income totaling USD 31.37M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 31.37M.
Fairly Valued
The company’s latest PE is -3.95, at a medium 3-year percentile range.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.03K shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
37.417
Target Price
+197.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
EyePoint Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
EyePoint Pharmaceuticals Inc Info
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Ticker SymbolEYPT
CompanyEyePoint Pharmaceuticals Inc
CEODuker (Jay S)
Websitehttps://eyepointpharma.com/
Related Instruments
-2.09%
-1.92%
+0.51%
+2.74%
+0.59%
-0.81%
-1.02%
-1.24%
-0.39%
-1.92%
-0.99%
+0.34%
-0.19%
-1.50%
-4.56%
0.00%
-0.54%
-2.51%
-2.81%
-0.83%Popular Symbols
248.800
-4.090 (-1.62%)
167.520
-3.720 (-2.17%)
66876.000
+885.240 (+1.34%)
275.340
+1.990 (+0.73%)
2022.090
+38.550 (+1.94%)
361.830
-10.280 (-2.76%)
4492.520
+112.460 (+2.57%)
100.609
+7.287 (+7.81%)
1.151
-0.002 (-0.17%)
160.252
+0.465 (+0.29%)
